Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.

Abstract:

BACKGROUND:The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patients treated with RP as the primary treatment option. METHODS:In a multi-institutional cohort, 266 patients with very high-risk cT3b/4 PCa treated with RP were identified. All patients underwent RP and pelvic lymph-node dissection. Competing-risk analyses assessed 10-year CSM and OCM before and after stratification for age and Charlson comorbidity index (CCI). RESULTS:Overall, 34 (13%) patients died from PCa and 73 (28%) from OCM. Ten-year CSM and OCM rates ranged from 5.6% to 12.9% and from 10% to 38%, respectively. OCM was the leading cause of death in all subgroups. Age and comorbidities were the main determinants of OCM. In healthy men, CSM rate did not differ among age groups (10-year CSM rate for ⩽64, 65-69 and ⩾70 years: 16.2%, 11.5% and 17.1%, respectively). Men with a CCI ⩾1 showed a very low risk of CSM irrespective of age (10-year CSM: 5.6-6.1%), whereas the 10-year OCM rates increased with age up to 38% in men ⩾70 years. CONCLUSION:Very high-risk cT3b/4 PCa represents a heterogeneous group. We revealed overall low CSM rates despite the highly unfavorable clinical disease. For healthy men, CSM was independent of age, supporting RP even for older men. Conversely, less healthy patients had the highest risk of dying from OCM while sharing very low risk of CSM, indicating that this group might not benefit from an aggressive surgical treatment. Outcome after RP as the primary treatment option in cT3b/4 PCa patients is related to age and comorbidity status.

authors

Moltzahn F,Karnes J,Gontero P,Kneitz B,Tombal B,Bader P,Briganti A,Montorsi F,Van Poppel H,Joniau S,Spahn M

doi

10.1038/pcan.2014.41

subject

Has Abstract

pub_date

2015-03-01 00:00:00

pages

31-7

issue

1

eissn

1365-7852

issn

1476-5608

pii

pcan201441

journal_volume

18

pub_type

杂志文章,多中心研究
  • Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project.

    abstract:BACKGROUND:Several treatment options for clinically localized prostate cancer currently exist under the established guidelines. We aim to assess nationally representative trends in treatment over time and determine potential geographic variation using two large national claims registries. METHODS:Men with prostate can...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2015.3

    authors: Cary KC,Punnen S,Odisho AY,Litwin MS,Saigal CS,Cooperberg MR,NIDDK Urologic Diseases in America Project.

    更新日期:2015-06-01 00:00:00

  • Magnetic resonance imaging in prostate cancer.

    abstract::With the recently published National Institute of Clinical Excellence guidelines, it is now generally accepted that magnetic resonance imaging (MRI) is the imaging method of choice for staging prostate cancer in patients for whom radical treatment is being considered. MRI offers the single most accurate assessment of ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/sj.pcan.4500767

    authors: Heenan SD

    更新日期:2004-01-01 00:00:00

  • Insulin-like Growth Factor (IGF) Network and Prostate Pathologies.

    abstract::The Insulin-like Growth Factor (IGF) network in prostate tissue represents a key element in normal and tumour growth. It can provide us with new markers for prognosis or diagnosis and targets for treatment of prostate diseases. This short review introduces the IGF network in general and in the prostate gland, summaris...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500295

    authors: Tatoud R

    更新日期:1999-03-01 00:00:00

  • MRI in active surveillance: a critical review.

    abstract:INTRODUCTION:Recent technological advancements and the introduction of modern anatomical and functional sequences have led to a growing role for multiparametric magnetic resonance imaging (mpMRI) in the detection, risk assessment and monitoring of early prostate cancer. This includes men who have been diagnosed with lo...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/s41391-018-0077-2

    authors: Stavrinides V,Giganti F,Emberton M,Moore CM

    更新日期:2019-03-01 00:00:00

  • Prostate activity and prostate cancer in spinal cord injury.

    abstract::In addition to androgen, autonomic nerves may be involved in prostatic function. As patients with spinal cord injury (SCI) have impaired innervation of the prostate, the prostate volume and prostate-specific antigen (PSA) level in patients with SCI may be different from those of healthy men. Experiments in rats with S...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/sj.pcan.4500865

    authors: Shim HB,Jung TY,Lee JK,Ku JH

    更新日期:2006-01-01 00:00:00

  • Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy.

    abstract:BACKGROUND:The Gleason grading system in prostatectomy specimens following receipt of neoadjuvant therapy has been considered inaccurate. However, with continuing expansion of novel therapeutics, it is important to understand whether the Gleason system can be effectively utilized in this setting. The aim of this study ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2014.30

    authors: Stewart SB,Cheville JC,Sebo TJ,Frank I,Boorjian SA,Thompson RH,Gettman MT,Tollefson MK,Umbriet EC,Psutka SP,Bergstralh EJ,Rangel L,Karnes RJ

    更新日期:2014-12-01 00:00:00

  • Tailored postoperative treatment of prostate cancer: final results of a phase I/II trial.

    abstract:BACKGROUD:The European Organization for Research and Treatment of Cancer (EORTC) trial 22,911 reported 74% 5-year biochemical disease-free survival (bDFS) in patients with prostate carcinoma treated with radical prostatectomy (RP) followed by postoperative radiotherapy (RT). This study aimed to improve these outcomes b...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-018-0064-7

    authors: Mantini G,Siepe G,Alitto AR,Buwenge M,Nguyen NP,Farioli A,Schiavina R,Catucci F,Deodato F,Fionda B,Frascino V,Macchia G,Ntreta M,Padula GDA,Arcelli A,Cammelli S,Rambaldi GZ,Cilla S,Valentini V,Morganti AG

    更新日期:2018-11-01 00:00:00

  • Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines.

    abstract::Stromal expression of some matrix metalloproteinases (MMPs) has been associated with increasing tumour burden in prostate cancer. We investigated the expression of mRNA (by RT-PCR) and protein (by zymography and western blotting) of MMPs and endogenous inhibitors (tissue inhibitors of metalloproteinases, TIMPs) in two...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500609

    authors: Daja MM,Niu X,Zhao Z,Brown JM,Russell PJ

    更新日期:2003-01-01 00:00:00

  • A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.

    abstract:BACKGROUND:In men with high Gleason PC and rapid PSA progression after surgery, failure rates remain unacceptably high despite salvage radiation. We explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiotherapy (RT). METHODS:This was a phase 2 single-arm prospective open...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2015.59

    authors: Armstrong AJ,Halabi S,Healy P,Lee WR,Koontz BF,Moul JW,Mundy K,Creel P,Wood S,Davis K,Carducci MA,Stein M,Hobbs C,Reimer B,Nguyen M,Anand M,Bratt L,Kim S,Tran PT,George DJ,Department of Defense Prostate Cancer Cli

    更新日期:2016-03-01 00:00:00

  • Contemporary management of men with high-risk localized prostate cancer in the United States.

    abstract::This corrects the article DOI: 10.1038/pcan.2017.5. ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,已发布勘误

    doi:10.1038/pcan.2017.35

    authors: Weiner AB,Matulewicz RS,Schaeffer EM,Liauw SL,Feinglass JM,Eggener SE

    更新日期:2017-12-01 00:00:00

  • 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.

    abstract::This literature review discusses the theoretical background of 5alpha-reductase inhibitor (5ARI) treatment and the resulting clinical implications. A Medline-based search for peer-reviewed articles addressing 5ARIs, benign prostatic hyperplasia and prostate cancer was performed. The 5ARIs Finasteride and Dutasteride, ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/pcan.2008.56

    authors: Dörsam J,Altwein J

    更新日期:2009-01-01 00:00:00

  • Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.

    abstract:BACKGROUND:Patients with prostate cancer are at risk of impaired bone health. Prostate cancer has a propensity to metastasize to bone, after which patients are at risk of skeletal-related events (SREs). These complications are associated with increased mortality, substantial pain, and reduced quality of life. Patients ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-018-0060-y

    authors: Miller K,Steger GG,Niepel D,Lüftner D

    更新日期:2018-11-01 00:00:00

  • Effects of hCG stimulation after withdrawal of long-term oestrogen treatment in patients with prostate carcinoma.

    abstract::Testosterone depletion is the keystone for therapy of patients metastic prostatic carcinoma. Our objective was to investigate Leydig cell function and testosterone levels after withdrawal of long-term endocrine treatment in patients with prostatic carcinoma. Thirteen patients with prostatic carcinoma, previously treat...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500310

    authors: Tomic R,Ljungberg B

    更新日期:1999-07-01 00:00:00

  • Adiponectin inhibits oxidative stress in human prostate carcinoma cells.

    abstract:BACKGROUND:Emerging data suggest that obesity increases the risk of aggressive prostate cancer (PC), but the mechanisms underlying this relationship remain to be fully elucidated. Oxidative stress (OS) is a key process in the development and progression of PC. Adiponectin, an adipocyte-specific hormone, circulates at r...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2011.53

    authors: Lu JP,Hou ZF,Duivenvoorden WC,Whelan K,Honig A,Pinthus JH

    更新日期:2012-03-01 00:00:00

  • Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients.

    abstract:INTRODUCTION:Treatment options for lymph node positive prostate cancer are limited. We retrospectively compared patients who underwent external radiotherapy (ERT) to patients treated by radical prostatectomy (RPX). MATERIALS AND METHODS:A total of 102 lymph node positive patients from the RPX series at Ulm University ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500751

    authors: Kuefer R,Volkmer BG,Loeffler M,Shen RL,Kempf L,Merseburger AS,Gschwend JE,Hautmann RE,Sandler HM,Rubin MA

    更新日期:2004-01-01 00:00:00

  • Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist.

    abstract:BACKGROUND:Gonadotrophin releasing hormone (GnRH) agonists and antagonists reduce testosterone levels for the treatment of advanced and metastatic prostate cancer. Androgen deprivation therapy (ADT) is associated with increased risk of cardiovascular (CV) events and CV disease (CVD), especially in patients with preexis...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-020-0264-9

    authors: Margel D,Ber Y,Peer A,Shavit-Grievink L,Pinthus JH,Witberg G,Baniel J,Kedar D,Rosenbaum E

    更新日期:2020-07-31 00:00:00

  • Upregulation of erythropoietin receptor in human prostate carcinoma and high-grade prostatic intraepithelial neoplasia.

    abstract::The aim of the present study was to investigate the differential expression of erythropoietin receptor (EPOR) in prostate carcinoma (PCa), high-grade prostatic intraepithelial neoplasia (PIN), prostatic hyperplasia (BPH) lesions and normal prostatic tissues by immunohistochemistry; and to test the hypothesis that upre...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500995

    authors: Zhou T,Xu C,He M,Sun Y

    更新日期:2008-01-01 00:00:00

  • Defining a role for the inhibitors of apoptosis proteins in prostate cancer.

    abstract::The aim of this paper is to review the inhibitors of apoptosis proteins, a recently discovered group of caspase inhibitors. We will briefly review the relevance of apoptosis in prostate cancer and some of the control mechanisms, before describing the structure, function and regulation of these molecules. Lastly, we wi...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500502

    authors: McEleny KR,Watson RW,Fitzpatrick JM

    更新日期:2001-01-01 00:00:00

  • Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer.

    abstract:BACKGROUND:Understanding the mechanisms driving disease progression is fundamental to identifying new therapeutic targets for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). Owing to the prevalence of bone metastases in mCRPC, obtaining sufficient tumor tissue for analysis has histori...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2014.28

    authors: McKay RR,Zukotynski KA,Werner L,Voznesensky O,Wu JS,Smith SE,Jiang Z,Melnick K,Yuan X,Kantoff PW,Montgomery B,Balk SP,Taplin ME

    更新日期:2014-12-01 00:00:00

  • Histopathological findings after radiofrequency (RITA) treatment for prostate cancer.

    abstract::Radiofrequency interstitial tumor ablation (RITA) is a thermal ablation method that uses needles and low radiofrequency (RF) energy. The aim of our study was to evaluate the histopathology of thermal lesions induced by RF energy delivered interstitially in prostate cancer patients who subsequently underwent prostatect...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500877

    authors: Patriarca C,Bergamaschi F,Gazzano G,Corrada P,Ordesi G,Zanitzer L,Di Pasquale M,Giunta P,Campo B

    更新日期:2006-01-01 00:00:00

  • Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy.

    abstract::Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored asso...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2009.61

    authors: Kyrdalen AE,Dahl AA,Hernes E,Cvancarova M,Fosså SD

    更新日期:2010-06-01 00:00:00

  • Association of diet and lifestyle with chronic prostatitis/chronic pelvic pain syndrome and pain severity: a case-control study.

    abstract:BACKGROUND:Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common problem with unclear etiology. Some diet and lifestyle factors were thought to correlate with CP/CPPS, but studies comprehensively investigate this correlation are rarely available. The current study was conducted to determine the potenti...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2015.57

    authors: Chen X,Hu C,Peng Y,Lu J,Yang NQ,Chen L,Zhang GQ,Tang LK,Dai JC

    更新日期:2016-03-01 00:00:00

  • A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.

    abstract:BACKGROUND:Intermittent androgen suppression (IAS) is an increasingly popular treatment option for castrate-sensitive prostate cancer. On the basis of previous data with anti-angiogenic strategies, we hypothesized that pan-inhibition of the vascular endothelial growth factor receptor using pazopanib during the IAS off ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/pcan.2011.49

    authors: Ward JE,Karrison T,Chatta G,Hussain M,Shevrin D,Szmulewitz RZ,O'Donnell PH,Stadler WM,Posadas EM

    更新日期:2012-03-01 00:00:00

  • Active surveillance for intermediate-risk prostate cancer.

    abstract:BACKGROUND:Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond typical men with very low- or low-risk disease. We sought to review the current experience with AS for men with int...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,meta分析,评审

    doi:10.1038/pcan.2016.51

    authors: Dall'Era MA,Klotz L

    更新日期:2017-03-01 00:00:00

  • Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE-/-:Ins2+/Akita mouse model.

    abstract:BACKGROUND:Unlike in other mouse models of atherogenesis, it has recently been suggested that orchiectomy plays a role in accelerating atherosclerosis and inhibiting the progression of cardiovascular disease in the ApoE-/-:Ins2+/Akita mouse model of hyperglycemia. Androgen-deprivation therapy (ADT) is a common treatmen...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-020-00288-y

    authors: Duivenvoorden WCM,Naeim M,Hopmans SN,Yousef S,Werstuck GH,Dason S,Pinthus JH

    更新日期:2020-09-28 00:00:00

  • Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.

    abstract:BACKGROUND:Patients with bone metastases secondary to prostate cancer are predisposed to skeletal-related events (SREs), including spinal cord compression, pathological fracture, surgery to bone and radiotherapy to bone. The objective of this study was to document current patterns of healthcare utilization and costs of...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2012.42

    authors: Hagiwara M,Delea TE,Saville MW,Chung K

    更新日期:2013-03-01 00:00:00

  • Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.

    abstract:OBJECTIVES:Neuroendocrine prostate cancers (NEPCs) are rare. The current lack of consensus for clinical, biological and pathological characterization as well as therapeutic approach makes the management of those tumors a clinical challenge. This literature review aims to summarize available data on the characterization...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,meta分析,评审

    doi:10.1038/pcan.2014.17

    authors: Sargos P,Ferretti L,Gross-Goupil M,Orre M,Cornelis F,Henriques de Figueiredo B,Houédé N,Merino C,Roubaud G,Dallaudiére B,Richaud P,Fléchon A

    更新日期:2014-09-01 00:00:00

  • The role of candidate genetic polymorphisms in the etiology of prostate cancer.

    abstract::Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identification of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to ide...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500471

    authors: Neuhausen SL

    更新日期:2000-12-01 00:00:00

  • Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases.

    abstract:BACKGROUND:In an era of multiple life-prolonging therapies for metastatic castration resistant prostate cancer (mCRPC), the optimal timing of initiation and duration of antiresorptive bone targeted therapy (BTT) to prevent skeletal related events (SREs) is unknown. METHODS:To assess practice patterns of BTT use and it...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-020-00280-6

    authors: McGregor B,Zhang L,Gray KP,Shaw G,Evan C,Francini E,Sweeney C

    更新日期:2020-09-03 00:00:00

  • Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.

    abstract::We hypothesized that factors beyond pathological stage, grade, PSA and margin status would be important predictors of biochemical recurrence (BCR) after radical prostatectomy (RP). A cohort of 3194 patients who underwent RP between 1988 and 2007 and who had neither neoadjuvant therapy nor postoperative adjuvant hormon...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2008.18

    authors: Schroeck FR,Sun L,Freedland SJ,Jayachandran J,Robertson CN,Moul JW

    更新日期:2008-01-01 00:00:00